Wiegmann, Thomas
3 papers on CoChat
Most cited papers
- Verified
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 3,163
- Verified
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 638
- Verified
Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study
Barzilay, J. I., Davis, B. R., Bettencourt, J., Margolis, K. L., Goff, D. C., Black, H., Habib, G., Ellsworth, A., Force, R. W., Wiegmann, T., et al. (2004) · The Journal of Clinical Hypertension
Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 70
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free